Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF Profit Margin

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's profit margin stands at 8.04% as of March 2026. That compares with 14.27% in the prior-year period — down 43.6% year over year. That is below the sector sector average of 19.69%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF reported 8.04% in profit margin versus 14.27% a year earlier — a 43.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF sits lower the its sector benchmark (19.69%) with a profit margin of 8.04%. That is roughly 59.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 8.04% for Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's profit margin evolved across reporting periods, while the comparison chart places GERM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.